# Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

> **NCT01420926** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 165 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Therapy-Related Acute Myeloid Leukemia

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Decitabine
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT01420926
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-16
- **Primary completion:** 2016-06-05
- **Final completion:** 2021-04-01
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01420926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01420926, "Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01420926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*